Lancet Global Health最新文献

筛选
英文 中文
Correction to Lancet Glob Health 2025; 13: e808-19. 《柳叶刀全球健康2025》更正;13: e808-19。
IF 19.9 1区 医学
Lancet Global Health Pub Date : 2025-05-12 DOI: 10.1016/S2214-109X(25)00182-2
{"title":"Correction to Lancet Glob Health 2025; 13: e808-19.","authors":"","doi":"10.1016/S2214-109X(25)00182-2","DOIUrl":"https://doi.org/10.1016/S2214-109X(25)00182-2","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":" ","pages":""},"PeriodicalIF":19.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Glob Health 2025; 13: e635-45. 《柳叶刀全球健康2025》更正;13: e635-45。
IF 19.9 1区 医学
Lancet Global Health Pub Date : 2025-05-12 DOI: 10.1016/S2214-109X(25)00172-X
{"title":"Correction to Lancet Glob Health 2025; 13: e635-45.","authors":"","doi":"10.1016/S2214-109X(25)00172-X","DOIUrl":"https://doi.org/10.1016/S2214-109X(25)00172-X","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":" ","pages":""},"PeriodicalIF":19.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racisms in a global health context. 全球卫生背景下的种族主义。
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-12 DOI: 10.1016/s2214-109x(25)00145-7
Delan Devakumar,Sonora English,Ananda Galappatti,Nora Groce,Weeam S Hammoudeh,Rudzani Muloiwa,Javier Rodriguez,Nidhi S Sabharwal,Priscila Sato,Jonathan Wells
{"title":"Racisms in a global health context.","authors":"Delan Devakumar,Sonora English,Ananda Galappatti,Nora Groce,Weeam S Hammoudeh,Rudzani Muloiwa,Javier Rodriguez,Nidhi S Sabharwal,Priscila Sato,Jonathan Wells","doi":"10.1016/s2214-109x(25)00145-7","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00145-7","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"141 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forging medical treatment partnerships to enhance PHC clinical trials in China. 建立医疗合作伙伴关系,加强初级保健在中国的临床试验。
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-08 DOI: 10.1016/s2214-109x(25)00181-0
Zhicheng Wang,Rizhen Wang,Qianyi Xia,Yangmu Huang
{"title":"Forging medical treatment partnerships to enhance PHC clinical trials in China.","authors":"Zhicheng Wang,Rizhen Wang,Qianyi Xia,Yangmu Huang","doi":"10.1016/s2214-109x(25)00181-0","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00181-0","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"50 1","pages":""},"PeriodicalIF":34.3,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Was the decline in Neisseria gonorrhoeae prevalence in the STICH trial real? STICH试验中淋病奈瑟菌患病率的下降是真实的吗?
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-01 DOI: 10.1016/s2214-109x(25)00099-3
Chris Richard Kenyon
{"title":"Was the decline in Neisseria gonorrhoeae prevalence in the STICH trial real?","authors":"Chris Richard Kenyon","doi":"10.1016/s2214-109x(25)00099-3","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00099-3","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"9 1","pages":"e804"},"PeriodicalIF":34.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Was the decline in Neisseria gonorrhoeae prevalence in the STICH trial real? - Authors' reply. STICH试验中淋病奈瑟菌患病率的下降是真实的吗?-作者的答复。
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-01 DOI: 10.1016/s2214-109x(25)00100-7
Chido Dziva Chikwari,Victoria Simms,Richard J Hayes,Rashida A Ferrand
{"title":"Was the decline in Neisseria gonorrhoeae prevalence in the STICH trial real? - Authors' reply.","authors":"Chido Dziva Chikwari,Victoria Simms,Richard J Hayes,Rashida A Ferrand","doi":"10.1016/s2214-109x(25)00100-7","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00100-7","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"19 1","pages":"e805"},"PeriodicalIF":34.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiologically based serum ferritin thresholds for iron deficiency among women and children from Africa, Asia, Europe, and central America: a multinational comparative study. 非洲、亚洲、欧洲和中美洲妇女和儿童铁缺乏的生理基础血清铁蛋白阈值:一项跨国比较研究。
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-01 DOI: 10.1016/s2214-109x(25)00009-9
O Yaw Addo,Zuguo Mei,Maria Elena D Jefferds,Mica Jenkins,Rafael Flores-Ayala,Anne M Williams,Melissa Fox Young,Hanqi Luo,Yi-An Ko,Ioannis Papassotiriou,Mireya Palmieri,Karla Mesarina,Zulfiqar Bhutta,Parminder S Suchdev,Gary M Brittenham
{"title":"Physiologically based serum ferritin thresholds for iron deficiency among women and children from Africa, Asia, Europe, and central America: a multinational comparative study.","authors":"O Yaw Addo,Zuguo Mei,Maria Elena D Jefferds,Mica Jenkins,Rafael Flores-Ayala,Anne M Williams,Melissa Fox Young,Hanqi Luo,Yi-An Ko,Ioannis Papassotiriou,Mireya Palmieri,Karla Mesarina,Zulfiqar Bhutta,Parminder S Suchdev,Gary M Brittenham","doi":"10.1016/s2214-109x(25)00009-9","DOIUrl":"https://doi.org/10.1016/s2214-109x(25)00009-9","url":null,"abstract":"BACKGROUNDDiagnosis of iron deficiency commonly relies on measurement of serum ferritin concentrations. WHO guidelines identify serum ferritin thresholds for iron deficiency among healthy individuals of less than 15 μg/L for women and less than 12 μg/L for children under 5 years, based on expert opinion. We report thresholds for iron deficiency for apparently healthy non-pregnant women and young children based on physiological indicators.METHODSWe performed secondary analyses of cross-sectional data from women (aged 15-49 years) and children (aged 6-59 months) from 12 countries in Africa, Asia, Europe, and central America from available surveys (2007-19). Using haemoglobin and soluble transferrin receptor concentrations as individual-level indicators of iron deficiency, we identified country-specific serum ferritin thresholds. We conducted multivariate meta-analysis using individual participant data to assess multinational heterogeneity and intercountry consistency.FINDINGSData were collected from July, 2007 to March, 2019. 18 251 individuals (13 864 women and 4387 children) were included in the final analysis. The thresholds of pooled serum ferritin levels corresponding to the starting point of decline in circulating haemoglobin concentrations were 24·8 μg/L (95% CI 24·4-25·2) for women and 22·1 μg/L (20·8-23·4) for children based on the national survey data from 12 countries. The thresholds were consistent among countries (pheterogeneity: women=0·73, children=0·43) but median serum ferritin concentrations and lower 5% reference ranges differed. In all countries, the prevalence of iron deficiency was higher using physiologically based thresholds than that using WHO current guidelines for women (36·0% [95% CI 25·3-46·8] vs 20·1% [11·5-28·7], p<0·0001) and for children (34·2% [24·3-44·1] vs 16·6% [11·2-22·0], p<0·0001).INTERPRETATIONThese results provide evidence that the prevalence of iron deficiency as indicated by physiological measures is substantially higher than those based on current WHO guidelines. The consistency of physiologically based serum ferritin thresholds in apparently healthy women and young children offers a potential means to achieve evidence-informed coordination in thresholds for iron deficiency across populations. The use of physiologically based serum ferritin thresholds could help in detecting the clinical and functional outcomes of iron deficiency.FUNDINGNone.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"83 1","pages":"e831-e842"},"PeriodicalIF":34.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study. 非昔硝唑治疗冈比亚人非洲锥虫病的有效性和安全性以及门诊患者依从性的探索:一项3b期、前瞻性、开放标签、非随机队列研究
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-01 DOI: 10.1016/s2214-109x(24)00526-6
Victor Kande Betu Kumeso,Christelle Perdrieu,Caroline Menétrey,Médard Ilunga Wa Kyhi,Digas Ngolo Tete,Mamadou Camara,John Tampwo,Papy Kavunga,Mariame Layba Camara,Ansoumane Kourouma,Willy Kuziena Mindele,Felix Akwaso Masa,Hélène Mahenzi,Joseph Makaya,Tim Mayala Malu,Guylain Mandula,Dieudonné Mpoyi Muamba Nzambi,Serge Luwawu Ntoya,Anne Reymondier,Wilfried Mutombo Kalonji,Bruno Scherrer,Olaf Valverde Mordt
{"title":"Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study.","authors":"Victor Kande Betu Kumeso,Christelle Perdrieu,Caroline Menétrey,Médard Ilunga Wa Kyhi,Digas Ngolo Tete,Mamadou Camara,John Tampwo,Papy Kavunga,Mariame Layba Camara,Ansoumane Kourouma,Willy Kuziena Mindele,Felix Akwaso Masa,Hélène Mahenzi,Joseph Makaya,Tim Mayala Malu,Guylain Mandula,Dieudonné Mpoyi Muamba Nzambi,Serge Luwawu Ntoya,Anne Reymondier,Wilfried Mutombo Kalonji,Bruno Scherrer,Olaf Valverde Mordt","doi":"10.1016/s2214-109x(24)00526-6","DOIUrl":"https://doi.org/10.1016/s2214-109x(24)00526-6","url":null,"abstract":"BACKGROUNDIn previous clinical trials, oral fexinidazole treatment showed a favourable safety profile, while being easily administered and effective for most adult and paediatric patients with gambiense human African trypanosomiasis. The aim of this open-label cohort study was to investigate the effectiveness and safety of fexinidazole in a wider population of patients and to explore the feasibility of treating patients with gambiense human African trypanosomiasis outside the hospital setting.METHODSIn this phase 3b, prospective, open-label, non-randomised, cohort study, fexinidazole was administered orally as 600 mg tablets, in a dose regimen dependent on bodyweight. The study was conducted at eight treatment centres in the Democratic Republic of the Congo (seven of which enrolled patients) and one treatment centre in Guinea. Patients were either treated in hospital (in particular those excluded from earlier studies, such as women in their second or third trimester of pregnancy, or breastfeeding), or at home without direct medical supervision (but with the support of a caregiver). Patients were eligible for study inclusion if they met the following key criteria: aged at least 6 years; weighed at least 20 kg; had trypanosomes detected in any body fluid; had a Karnofsky performance status higher than 40%; were able to comply with the schedule of follow-up visits and with the study constraints; and were willing to undergo lumbar punctures. The primary endpoint was treatment outcome at 18 months, based on absence of parasites in lumbar puncture and blood, and overall clinical status. This study has been completed and is registered with ClinicalTrials.gov, NCT03025789.FINDINGSBetween Nov 10, 2016, and Aug 10, 2019, 200 patients were screened, of whom 174 (87%) were included and received at least one tablet of fexinidazole: 136 patients treated in hospital and 38 treated at home. All patients but one completed treatment. At 18 months, treatment was effective in 162 (93%) of 174 patients (95% CI 88·3-96·4). No new safety signals were identified, including in the 24 women who took fexinidazole before or during pregnancy or during breastfeeding. All outpatients complied with the dosing regimen, although three (8%) of 38 completed their treatment at the hospital.INTERPRETATIONThe effectiveness and safety of fexinidazole in this wider population was similar to that described in previous clinical trials, and treatment at home seems feasible in selected patients who had the support of their caregiver.FUNDINGVarious donors through the Drugs for Neglected Diseases initiative.TRANSLATIONFor the French translation of the abstract see Supplementary Materials section.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"9 1","pages":"e900-e909"},"PeriodicalIF":34.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Data gaps in prevalence rates of mental health conditions around the world: a retrospective analysis of nationally representative data. 世界各地精神健康状况流行率方面的数据缺口:对具有国家代表性数据的回顾性分析。
IF 34.3 1区 医学
Lancet Global Health Pub Date : 2025-05-01 DOI: 10.1016/s2214-109x(24)00563-1
Caio B Casella,Antonis A Kousoulis,Brandon A Kohrt,Jason Bantjes,Christian Kieling,Pim Cuijpers,Sarah Kline,Konstantinos Kotsis,Guilherme V Polanczyk,Dan J Stein,Peter Szatmari,Kathleen R Merikangas,Zeina Mneimneh,Giovanni A Salum
{"title":"Data gaps in prevalence rates of mental health conditions around the world: a retrospective analysis of nationally representative data.","authors":"Caio B Casella,Antonis A Kousoulis,Brandon A Kohrt,Jason Bantjes,Christian Kieling,Pim Cuijpers,Sarah Kline,Konstantinos Kotsis,Guilherme V Polanczyk,Dan J Stein,Peter Szatmari,Kathleen R Merikangas,Zeina Mneimneh,Giovanni A Salum","doi":"10.1016/s2214-109x(24)00563-1","DOIUrl":"https://doi.org/10.1016/s2214-109x(24)00563-1","url":null,"abstract":"BACKGROUNDMental health conditions contribute substantially to the global burden of disease, affecting quality of life and leading to increased health-care expenses and mortality. Accurate data on the prevalence and correlates of these disorders are crucial for policy making, advocacy, and improving population health, but there are notable gaps in the available data on the magnitude of mental health difficulties around the world. This study aims to identify and quantify the data gaps on mental disorders across the lifespan in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021.METHODSWe analysed the nationally representative data sources used by GBD 2021 on 11 mental health conditions, including neurodevelopmental disorders and neurodivergence, general psychiatric disorders, and substance-use disorders. Our analysis focused on the geographical origin of the data sources, the age groups and mental health conditions or neurodivergence covered, and temporal trends on the scientific production of data.FINDINGSGBD 2021 identified 1241 unique nationally representative data sources for mental health conditions since 1950. Neurodevelopmental disorders and neurodivergence had the least coverage, with less than 13% of countries having prevalence data. Low-income countries had the largest data gap, with no data on neurodevelopmental disorders and neurodivergence, only 29% with any data on general psychiatric disorders, and 21% with data on substance-use disorders. The African and Western Pacific regions had the largest data gaps, and children were the least covered demographic: almost 90% of countries did not have any data for children. Most data (70-80% across disorders) were obtained before 2010.INTERPRETATIONSubstantial gaps in prevalence data persist globally, particularly in children and in low-income countries. Despite increased scientific production in the 2000s, most mental disorders remain under-represented. Coordinated global efforts are required to enhance mental health data collection and address these gaps.FUNDINGCoordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil.","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":"42 1","pages":"e879-e887"},"PeriodicalIF":34.3,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decentralised care: a promising strategy in managing Ebola outbreaks. 分散护理:管理埃博拉疫情的可行策略。
IF 19.9 1区 医学
Lancet Global Health Pub Date : 2025-05-01 Epub Date: 2025-03-25 DOI: 10.1016/S2214-109X(25)00019-1
Olushayo Oluseun Olu
{"title":"Decentralised care: a promising strategy in managing Ebola outbreaks.","authors":"Olushayo Oluseun Olu","doi":"10.1016/S2214-109X(25)00019-1","DOIUrl":"10.1016/S2214-109X(25)00019-1","url":null,"abstract":"","PeriodicalId":48783,"journal":{"name":"Lancet Global Health","volume":" ","pages":"e791-e792"},"PeriodicalIF":19.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信